The Gut Microbiota as Potential Therapeutic Targets for Synthetic Chemical Entities and Natural Products
A special issue of Molecules (ISSN 1420-3049). This special issue belongs to the section "Medicinal Chemistry".
Deadline for manuscript submissions: closed (31 March 2023) | Viewed by 7538
Special Issue Editor
Interests: natural products chemistry; pharmacology; drug discovery; pharmacognosy
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
The gut microbiota or the so called ‘hidden organ’ include several trillions of microbial counts in the human gut, which is predominantly composed of bacteria and to a less extent others, including fungi. Beyond aiding digestion, the microbiota and their products, such as short chain fatty acids (SCFAs), promote health through a variety of mechanisms, including through profound effects on the immune system. Changes in the gut microbiota structure and diversity could thus lead to several gastrointestinal problems, such as inflammatory bowel diseases and bowl cancer. Recent studies have also shown that dysbiosis of the gut microbiota is associated with the development of metabolic diseases ranging from obesity and diabetes to cardiovascular complications. There are also numerous central (e.g., neurodegenerative diseases) and peripheral diseases which trace their origin to changes to the gut microbiota. Accordingly, probiotics and/or other natural products that target the gut microbiota can be used either to promote health or reverse pathological conditions. Interestingly, variations in drug efficacy that used to be regarded of genetic origin have recently been established as those of environmental factors—predominantly due to variations in dietary habits that affect the structure/diversity of the gut the microbiota. Against such background, we have established this Special Issue: “The Gut Microbiota as Potential Therapeutic Targets for Synthetic Chemical Entities and Natural Products”, which will focus on:
- Large (carbohydrates, fats, proteins, fibers, etc.) and small molecular weight synthetic or natural products that promote health, and/or ameliorate diseases by targeting the gut microbiota;
- Crude natural products (e.g., well-characterized medicinal foods and plant extracts), purified compounds of synthetic or natural origin or drug combination approaches on targeting the gut microbiota;
- Molecules that enhance the bioavailability of drugs and biological agents through modulation of the gut microbiota;
- The medicinal chemistry of the gut microbiota modulators;
- Selective targeting of the gut microbiota by bioactive agents to improve the efficacy of therapeutic agents/approaches;
- Modulation of the gut microbiota products (e.g., SCFAs) by bioactive compounds and or potential drugs in health and disease;
- Molecules that modulate the gut microbiota diversity in human populations—on the way to personalized medicines;
- Experimental designs and protocols that aid research in the field.
We welcome contributions in the form of original research or review articles covering any aspects of the above topics but with special emphasis on chemistry/biochemistry of the disease or potential therapeutics.
Prof. Dr. Solomon Habtemariam
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- gut microbiota
- dysbiosis
- short chain fatty acids
- firmicutes-to-bacteroidetes ratio
- novel drugs
- novel targets
- probiotics
- prebiotics
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
